Investor Michal Zahradníček, co-founder of LIFE BioCEEd, has sold a unique European patent for processing umbilical cord blood to the German biotech company Vita 34 for hundreds of millions of crowns.

This transaction is not only a business success but also a strong signal of the global potential of Czech science and innovation. The patent enables broader use of stem cells in regenerative medicine and offers hope for the treatment of serious diseases, from leukemia to cerebral palsy and autism.

Read the full article on Seznam Zprávy: https://www.seznamzpravy.cz/clanek/ekonomika-firmy-uveril-vyzkumu-krve-kteremu-hrozil-konec-patent-prodal-za-stamiliony-277971